|
|
Article: Gemfibrozil reduces cardiac events in CHD patients with low HDL cholesterol but no other lipid risks
- Article from:
- Formulary
- Article date:
- January 1, 1999
- Author:
CopyrightCopyright Advanstar Communications, Inc. Jan 1999. Provided by ProQuest LLC. (Hide copyright information)
|
Gemfibrozil is a cost-effective treatment for reducing cardiac events in men with coronary heart disease (CHD) whose only lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol, reported Hanna Rubins, MD.
She presented results from the Veterans Administration HDL Intervention Trial (VA HIT), conducted in 2,531 men (mean age: 64) with CHD and the following lipid profile:
HDL cholesterol levels of 40 mg/dl or less,
low-density lipoprotein (LDL) cholesterol levels of 140 mg/dl or less, and
triglyceride levels of 300 mg/dl or less.
"This lipid profile represents about 25% of patients with heart disease," explained Dr. Rubins, chief of general internal medicine, VA ...